



BMSystems filed on Septembers 10, 2008, with CEA life Sciences, a patent application covering new therapeutic strategies and a preclinical evaluation platform in the field of psychiatric disorders

Paris, France, September 25, 2008 – The utilization of CADI*™ (biological modeling approach and technologies) leads to a new industrial success in CNS diseases. BMSystems filed on Septembers 10, 2008, with CEA life Sciences**, a ***patent application covering new therapeutic strategies and a preclinical evaluation platform in the field of psychiatric disorders.***

This shared patent illustrates the unique efficacy of BMSystems' proprietary CADI™ technologies, the excellence of the respective research teams and the successful application of the collaborative CADI™ four steps validation process.

After the successful launch and financing, in 2006, of its spin-off ***Pherecydes-Pharma*** (infectious diseases, 2 patents), Bio-Modeling Systems confirms the power of its business strategy to create immediate value through collaborations with partners.

We are also very proud of our strong scientific recognition in neurological sciences, materialised through the publication of the collaborative scientific reference textbook: ***Biomarkers for Psychiatric Disorders*** (Ref. ISBN: 978-0-387-79250-7, November 2008). Dr. François Iris is the author of the "Integrative Biology" chapter in this book. The editor, *Christoph W. Turck, is head of the Proteomics and Biomarkers branch at the Max Planck Institute of Psychiatry*

We warmly invite you to visit our new website www.bmsystems.net and download our new presentation with *three case studies* that illustrate through facts the capability of our CADI™ platform to really deliver.

*CADI™: Computer Assisted Deductive Integration; The predictive integrative biology approach invented & developed by BMSystems.

** CEA life Sciences: Atomic Energy Council Life Sciences unit, one of the major life sciences institutions in France

Looking forward meeting you in the near future,

Best regards,

Manuel GEA
Co-founder and CEO
BIO-MODELING SYSTEMS
Predictive Integrative Biology
26 rue Saint Lambert
75015 PARIS FRANCE
mobile: +33 (0)6 83 06 12 72
email: manuel.gea@bmsystems.net
web: www.bmsystems.net

About the Company:

Our mission : We help our clients and partners to significantly boost the outputs of their R&D programs using our modeling approach.

CADI™: The “first-in-class” answer to explain the non-linear mechanisms of diseases and thus, reveal pertinent biomarkers & therapeutic targets.

- 2003, CADI™ models “first-in-class”. Publication with INSERM unit 553 of the world’s first successful independently validated model of a complex human disease in Nucleic Acids Research.
- Mechanisms of life being integrative non-linear processes, they require “specific” approaches to be correctly understood: CADI™ models, belong to the non-mathematical class of models.
- CADI™ models building approach, based on the disruptive “negative selection” concept, and an innovative synergic collaboration between experimental biology and integrative biology has proven to allow researchers to take the best possible decisions for the best possible results in a minimum of time and resources.

BMSystems’ operational proofs. One approach for multiple validated applications***

- 7 CADI™ models produced in 5 major medical areas,
- 2 publications in “cancer” with INSERM unit 553,
- 1 patent in “psychiatric disorders” with CEA** Life Sciences,
- 1 scientific publication pending in “neurodegenerative diseases” with CEA** Life Sciences
- 2 patents in infectious diseases,
- 1 operational spin-off in Biodefense/Biosecurity (infectious threats),
- 2 technology platforms (pre-clinical evaluation for psychiatric molecules, industrial biotech),
- 2 bacterial strains under development.